OpenAlex
PricingAboutJobs
Log inGet started
Work

Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.

HTML

Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2020.38.15_suppl.tps3146
Authors: Jayesh Desai, Tarek Meniawy, Brandon Beagle, ZheZhen Li, Song Mu, John Wu, Crystal S. Denlinger, Wells A. Messersmith
Institutions: Peter MacCallum Cancer Centre, The University of Western Australia, Linear Clinical Research, Fox Chase Cancer Center, University of Colorado Health, University of Colorado Cancer Center, University of Colorado Anschutz
Language: English

Topic: Cancer Immunotherapy and Biomarkers
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: tislelizumab, TIM-3, PD-1, immune checkpoint blockade, combination immunotherapy, advanced solid tumors, antibody-dependent phagocytosis, Fc gamma receptor, T cell exhaustion, anticancer activity, safety and tolerability, pharmacokinetics, recommended phase 2 dose, tumor-infiltrating lymphocytes, tumor immune microenvironment
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W3029023398
Cites:
Cited by: 15
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms